14158 Results (Page 106 of 567)
All Market Research Reports
Singapore Atherosclerosis Therapeutics Market Analysis
Singapore Atherosclerosis Therapeutics Market was valued at $3 Mn in 2022 and is estimated to reach $5 Mn in 2030, exhibiting a CAGR of 6.3% during the forecast period. The increasing number of cardiovascular disease cases, which are exacerbated by poor dietary habits, sedentary lifestyles, and an aging global population, is predicted to drive up demand for atherosclerosis treatments. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott Laboratories, Eli Lilly, Eisai, Takeda and Mitsubishi Tanabe Pharma Corporation.
Saudi Arabia Atherosclerosis Therapeutics Market Analysis
Saudi Arabia Atherosclerosis Therapeutics Market was valued at $48 Mn in 2022 and is estimated to reach $83 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the increased incidence of sedentary behaviour, poor diets, and the aging of the world's population, which are all contributing factors to the prevalence of cardiovascular diseases. Top leading pharmaceutical companies currently operating in the market are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Johnson & Johnson, Eli Lilly, AbbVie, Roche and Amgen.
Philippines Atherosclerosis Therapeutics Market Analysis
Philippines Atherosclerosis Therapeutics Market was valued at $6 Mn in 2022 and is estimated to reach $10 Mn in 2030, exhibiting a CAGR of 6.2% during the forecast period. The increasing number of cardiovascular disease cases, which are exacerbated by poor dietary habits, sedentary lifestyles, and an aging global population, is predicted to drive up demand for atherosclerosis treatments. The top leading pharmaceutical companies presently operating in the industry are Novartis, Pfizer, AstraZeneca, Eisai, Merck Sharp & Dohme, Sanofi, Bayer, Abbott, Johnson & Johnson and Roche.
Mexico Atherosclerosis Therapeutics Market Analysis
Mexico Atherosclerosis Therapeutics Market was valued at $42 Mn in 2022 and is estimated to reach $67 Mn in 2030, exhibiting a CAGR of 5.95% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the growing incidence of cardiovascular diseases, which are being exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The market is currently dominated by leading pharmaceutical companies, including Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Johnson & Johnson, Teva Pharmaceutical, Roche, and Merck & Co.
Malaysia Atherosclerosis Therapeutics Market Analysis
Malaysia Atherosclerosis Therapeutics Market was valued at $5 Mn in 2022 and is estimated to reach $7 Mn in 2030, exhibiting a CAGR of 5.9% during the forecast period. The demand for atherosclerosis treatments is expected to rise due to the growing cases of cardiovascular diseases, escalated by unhealthy eating habits, inactive lifestyles, and a globally aging population. The top leading pharmaceutical companies presently operating in the industry are Novartis, Pfizer, AstraZeneca, Eisai, Merck Sharp & Dohme, Sanofi, Bayer, Abbott, Johnson & Johnson and Roche
Kenya Atherosclerosis Therapeutics Market Analysis
Kenya Atherosclerosis Therapeutics Market was valued at $2 Mn in 2022 and is estimated to reach $3 Mn in 2030, exhibiting a CAGR of 6.8% during the forecast period. The increasing prevalence of cardiovascular diseases, aggravated by unhealthy dietary patterns, sedentary lifestyles, and a growing aging population worldwide, is anticipated to increase the need for atherosclerosis therapeutics. Leading pharmaceutical companies currently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Eli Lilly, GlaxoSmithKline, Teva Pharmaceutical and Roche.
Japan Atherosclerosis Therapeutics Market Analysis
Japan Atherosclerosis Therapeutics Market was valued at $174 Mn in 2022 and is estimated to reach $282 Mn in 2030, exhibiting a CAGR of 6.2% during the forecast period. The demand for atherosclerosis treatments is expected to rise due to the growing cases of cardiovascular diseases, escalated by unhealthy eating habits, inactive lifestyles, and a globally aging population. The top leading pharmaceutical companies presently operating in the industry are Novartis, Eisai, AstraZeneca, Pfizer, Mitsubishi Tanabe Pharma Corporation, Merck Sharp & Dohme, Sanofi, Bayer, Daiichi Sankyo and Takeda Pharmaceutical Company.
Indonesia Atherosclerosis Therapeutics Market Analysis
Indonesia Atherosclerosis therapeutics market was valued at $17 Mn in 2022 and is estimated to reach $26 Mn in 2030, exhibiting a CAGR of 5.7% during the forecast period. The demand for atherosclerosis treatments is expected to rise due to the growing cases of cardiovascular diseases, escalated by unhealthy eating habits, inactive lifestyles, and a globally aging population. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, Sanofi, Merck, AstraZeneca, Bayer, PT Kalbe Farma, PT Kimia Farma, Eli Lilly and AbbVie.
Germany Atherosclerosis Therapeutics Market Analysis
Germany Atherosclerosis therapeutics market was valued at $102 Mn in 2022 and is estimated to reach $139 Mn in 2030, exhibiting a CAGR of 3.9% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the rising incidence of cardiovascular diseases, which are exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. Well-known pharmaceutical companies that presently hold a significant share of the market include Sanofi, Novartis, Pfizer, Bayer, AstraZeneca, Merck Sharp & Dohme, AbbVie, Roche, Johnson & Johnson, and Bristol-Myers Squibb
France Atherosclerosis Therapeutics Market Report 2022 to 2030
France Atherosclerosis Therapeutics Market was valued at $77 Mn in 2022 and is estimated to reach $111 Mn in 2030, exhibiting a CAGR of 4.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the rising incidence of cardiovascular diseases, which are exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The market is currently dominated by leading pharmaceutical companies, including Sanofi, Novartis, Pfizer, Bayer, AstraZeneca, Merck Sharp & Dohme, AbbVie, Roche, Johnson & Johnson and Bristol-Myers Squibb.
Egypt Atherosclerosis Therapeutics Market Analysis
Egypt Atherosclerosis Therapeutics Market was valued at $8 Mn in 2022 and is estimated to reach $14 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period. The rising prevalence of cardiovascular diseases, exacerbated by unhealthy dietary patterns, sedentary lifestyles, and a growing aging population worldwide, is anticipated to increase the need for atherosclerosis therapeutics. Leading pharmaceutical companies currently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Eli Lilly, GlaxoSmithKline, Teva Pharmaceutical, and Roche.
China Atherosclerosis Therapeutics Market Analysis
China Atherosclerosis Therapeutics Market was valued at $225 Mn in 2022 and is estimated to reach $393 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period. The market for atherosclerosis therapeutics is expected to rise as a result of the increasing prevalence of cardiovascular illnesses that have been exacerbated by unhealthy eating habits, sedentary lifestyles, and an aging population worldwide. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Merck & Co., China Resources Pharmaceutical Group, Huahai Pharmaceutical Group, Jiangsu Hengrui Medicine Co., Qilu Pharmaceutical Co. and Yisheng Pharmaceutical Co.
Canada Atherosclerosis Therapeutics Market Analysis
Canada Atherosclerosis Therapeutics Market was valued at $224 Mn in 2022 and is estimated to reach $349 Mn in 2030, exhibiting a CAGR of 5.7% during the forecast period. The increasing prevalence of cardiovascular diseases, driven by the global aging population and rising occurrences of sedentary behaviour and unhealthy diets, is expected to fuel the demand for atherosclerosis therapeutics. The leading pharmaceutical companies currently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Johnson & Johnson, Eli Lilly, AbbVie, Roche and Teva Pharmaceutical Industries
Brazil Atherosclerosis Therapeutics Market Analysis
Brazil Atherosclerosis Therapeutics Market was valued at $70 Mn in 2022 and is estimated to reach $118 Mn in 2030, exhibiting a CAGR of 6.7% during the forecast period. The market for atherosclerosis therapeutics is expected to grow as a result of the growing incidence of cardiovascular diseases, which are being exacerbated by sedentary lifestyles, poor eating habits, and an aging population worldwide. The leading pharmaceutical companies presently operating in the market are Pfizer, Novartis, AstraZeneca, Sanofi, Bayer, Abbott, Johnson & Johnson, Teva Pharmaceutical, Roche, and Merck & Co.
Vietnam Asthma and COPD Therapeutics Market Analysis
The Vietnam Asthma and COPD Therapeutics Market was valued at US $167 Mn in 2022, and is predicted to grow at (CAGR) of 5.43% from 2023 to 2030, to US $255 Mn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, supportive government initiatives, improved healthcare infrastructure, and others. The industry is primarily dominated by players such as Abbott, Mekophar, AstraZeneca, Traphaco, Novartis, Pharimexco, and GSK, among others.
US Asthma and COPD Therapeutics Market Analysis
The US Asthma and COPD Therapeutics Market was valued at US $14.03 Bn in 2022, and is predicted to grow at (CAGR) of 3.20% from 2023 to 2030, to US $18.05 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and asthma, advanced treatments, rising healthcare spending, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Teva US, GSK, Novartis Pfizer, and Boehringer Ingelheim, among others
UK Asthma and COPD Therapeutics Market Analysis
The UK Asthma and COPD Therapeutics Market was valued at US $0.868 Bn in 2022, and is predicted to grow at (CAGR) of 3.20% from 2023 to 2030, to US $1.117 Bn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, demand for effective treatment, supportive government initiatives, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Teva, GSK, Novartis Pfizer, Boehringer Ingelheim, among others
UAE Asthma and COPD Therapeutics Market Analysis
The UAE Asthma and COPD Therapeutics Market was valued at US $167 Mn in 2022, and is predicted to grow at (CAGR) of 6.20% from 2023 to 2030, to US $270 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, supportive government initiatives, unmet demand, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Teva, Merck Novartis, AstraZeneca, Pfizer, and Boehringer Ingelheim, among others.
Spain Asthma and COPD Therapeutics Market Analysis
The Spain Asthma and COPD Therapeutics Market was valued at US $645 Mn in 2022, and is predicted to grow at (CAGR) of 4.20% from 2023 to 2030, to US $896 Mn by 2030. The key drivers of this industry include the rising burden of COPD and asthma, the impact of the COVID-19 pandemic, supportive regulations, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Teva, Pfizer, Novartis, AbbVie, AstraZeneca, and Boehringer Ingelheim, among others
South Africa Asthma and COPD Therapeutics Market Analysis
The South Africa Asthma and COPD Therapeutics Market was valued at US $217 Mn in 2022, and is predicted to grow at (CAGR) of 6.43% from 2023 to 2030, to US $357 Mn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, supportive government initiatives, technological advancements, and others. The industry is primarily dominated by players such as Abbott, Aspen, AstraZeneca, Adcock, Novartis, Netcare, and GSK, among others.
Singapore Asthma and COPD Therapeutics Market Analysis
The Singapore Asthma and COPD Therapeutics Market was valued at US $40 Mn in 2022, and is predicted to grow at (CAGR) of 5.80% from 2023 to 2030, to US $63 Mn by 2030. The key drivers of this industry include the rise in the prevalence of COPD and asthma, growth in disposable income, increased awareness, and others. The industry is primarily dominated by players such as AstraZeneca, Teva, Novartis, GlaxoSmithKline, and Boehringer Ingelheim, among others.
Saudi Arabia Asthma and COPD Therapeutics Market Analysis
The Saudi Arabia Asthma and COPD Therapeutics Market was valued at US $568 Mn in 2022, and is predicted to grow at (CAGR) of 6.70% from 2023 to 2030, to US $954 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and Asthma, advanced treatments, rising healthcare spending, and others. The industry is primarily dominated by players such as, Novartis, Teva, GSK, Novartis, AstraZeneca, Pfizer, and Boehringer Ingelheim, among others
Philippines Asthma and COPD Therapeutics Market Analysis
The Philippines Asthma and COPD Therapeutics Market was valued at US $73 Mn in 2022, and is predicted to grow at (CAGR) of 5.70% from 2023 to 2030, to US $114 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, growing collaborations, improved healthcare infrastructure, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Teva, Sanofi, Pfizer, and GlaxoSmithKline, among others.
Mexico Asthma and COPD Therapeutics Market Analysis
The Mexico Asthma and COPD Therapeutics Market was valued at US $501 Mn in 2022, and is predicted to grow at (CAGR) of 5.45% from 2023 to 2030, to US $766 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of COPD and asthma, increasing demand, supportive policies, and others. The industry is primarily dominated by players such as, GlaxoSmithKline, Tetherex, Novartis, AstraZeneca, Verona, and Boehringer Ingelheim, among others
Malaysia Asthma and COPD Therapeutics Market Analysis
The Malaysia Asthma and COPD Therapeutics Market was valued at US $54 Mn in 2022, and is predicted to grow at (CAGR) of 5.40% from 2023 to 2030, to US $82 Mn by 2030. The key drivers of this industry include the rising prevalence of COPD and asthma, supportive government initiatives, improved healthcare infrastructure, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Chiesi, Sanofi, Pfizer, and GlaxoSmithKline, among others.
